优化急性缺血性卒中溶栓治疗:辅助治疗与多剂量策略
本综述总结急性缺血性卒中静脉溶栓(IVT)多剂量策略及辅助治疗证据,包括非取栓候选者重复IVT、IVT或动脉内溶栓联合血管内取栓(EVT)。抗血栓辅助治疗未显示一致获益,替奈普酶较阿替普酶至多边际改善结局。新兴数据支持新型纤溶药物、序贯IVT剂量和辅助动脉内溶栓作为有前景策略。
要点
- IVT与EVT是急性缺血性卒中治疗基石,但常未能实现持续再通和微血管灌注。
- 抗血栓药物辅助IVT未显示一致获益,替奈普酶较阿替普酶仅边际改善结局。
- 新型纤溶药物、序贯IVT剂量和辅助动脉内溶栓是增强再灌注的有前景策略。
核心结论
- 新兴数据支持新型纤溶药物、序贯IVT剂量和辅助动脉内溶栓作为增强再灌注和功能恢复同时保持安全性的有前景策略。
研究设计与样本
- 综述总结当前IVT多剂量策略证据,包括非EVT候选者重复IVT及IVT或动脉内溶栓联合EVT。
主要发现
- 抗血栓治疗辅助IVT未显示一致获益。
- 替奈普酶较阿替普酶至多边际改善结局。
- IVT和EVT常未能实现持续再通、微血管灌注和最佳临床结局。
局限性
- 综述识别知识空白以指导未来研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Intravenous thrombolysis (IVT) and endovascular thrombectomy (EVT) are the keystones of current treatment for acute ischemic stroke. Most IVT candidates harbor medium or distal arterial occlusions, while EVT targets large artery occlusions. However, both treatments often fail to achieve sustained recanalization, microvascular reperfusion, and optimal clinical outcomes. Supplementing IVT with antithrombotic therapies has not shown consistent benefit, and alternative lytics such as tenecteplase provide, at best, a marginal improvement in outcome compared with alteplase. This review summarizes current evidence on multiple dosing strategies of IVT, including repeat administration of IVT in non-EVT candidates and IVT or intra-arterial thrombolytics in combination with EVT. We discuss the physiologic, pharmacokinetic, and clinical rationale for these approaches, highlight results from key clinical trials, and identify knowledge gaps to guide future research. Emerging data support novel fibrinolytic agents, sequential IVT dosing, and adjunct intra-arterial thrombolysis as promising strategies to enhance reperfusion and functional recovery while maintaining safety.
引用
- Shahrivari M, Grotta JC. Optimizing Thrombolysis for Acute Ischemic Stroke: Adjunct Therapies and Multiple Dosing Strategies. Neurology. 2026. PMID: 42525907. doi:10.1212/WNL.0000000000218285
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。